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bjectives This study aimed to evaluate the degradation rate and long-term vascular responses to
he absorbable metal stent (AMS).
ackground The AMS demonstrated feasibility and safety at 4 months in human coronary arteries.
ethods The PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting)
as a prospective, multicenter clinical trial of 63 patients with coronary artery disease who under-
ent AMS implantation. Angiography and intravascular ultrasound (IVUS) were conducted immedi-
tely after AMS deployment and at 4 months. Eight patients who did not require repeat revascular-
zation at 4 months underwent late angiographic and IVUS follow-up from 12 to 28 months.
esults The AMS was well-expanded upon deployment without immediate recoil. The major contribu-
ors for restenosis as detected by IVUS at 4 months were: decrease of external elastic membrane volume
42%), extra-stent neointima (13%), and intra-stent neointima (45%). From 4 months to late follow-up,
aired IVUS analysis demonstrated complete stent degradation with durability of the 4-month IVUS in-
exes. The neointima was reduced by 3.6  5.2 mm3, with an increase in the stent cross sectional area
f 0.5  1.0 mm2 (p  NS). The median in-stent minimal lumen diameter was increased from 1.87 to
.17 mm at long-term follow-up. The median angiographic late loss was reduced from 0.62 to 0.40 mm
y quantitative coronary angiography from 4 months to late follow-up.
onclusions Intravascular ultrasound imaging supports the safety proﬁle of AMS with degradation
t 4 months and maintains durability of the results without any early or late adverse ﬁndings.
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313oronary stents are used as a mechanical means to over-
ome the major limitations of balloon angioplasty with
nabling scaffolding and the prevention of early recoil and
ate vascular remodeling (1,2). The major limitations of
tents are chronic inflammation, thrombosis, and restenosis,
n association with artifact in noninvasive imaging of com-
uterized tomography (CT) or magnetic resonance imaging
MRI) (3–5). Drug-eluting stents (DES) were introduced
o minimize the restenosis and revascularization rates of
etallic stents (6–9). However, DES were reported to be
ssociated with delayed healing, inflammation, hypersensi-
ivity to the drug or to the polymer, and endothelial
ysfunction, which have contributed to the late thrombosis
nd perhaps mortality and mandated prolonged dual anti-
latelet therapy (10–13). Nevertheless, the need for scaf-
olding is temporary and limited to the intervention and
hortly thereafter, until healing and re-endothelialization
s obtained. Beyond that, no utility or advantage for
tents has been demonstrated, and their presence could be
nidus for late thrombosis and chronic inflammation.
Absorbable metal stents (AMS) were designed to overcome
hese drawbacks. Animal experiments demonstrated com-
lete and rapid re-endothelialization, low neointima pro-
iferation, and less inflammation when compared with
etallic stents (14,15). The AMS are not associated with
ny imaging artifact with CT or MRI (16,17). The AMS
nitial clinical experience was in tibial arteries and demon-
trated an excellent safety profile and acceptable patency
ates at 24 months (18,19). This led to the initiation of the
rst trial to treat human coronary lesions with AMS, named
ROGRESS-AMS (Clinical Performance and Angio-
raphic Results of Coronary Stenting with Absorbable
etal Stents) (20).
The PROGRESS-AMS study demonstrated that biode-
radable magnesium stents can be implanted safely and that
he stents degraded as intended without stent thrombosis,
yocardial infarction, or death at 1 year (20). However, the
tudy was associated with high angiographic restenosis rates
f in-stent diameter stenosis (DS) (48.2  17.0%) and
n-segment late loss (0.83  0.51 mm), which led to
schemic-driven target lesion revascularization of 23.8% at 4
onths and 27.9% at 1 year. The objective of this study was
o evaluate the mechanisms that contributed to restenosis of
he AMS and the long-term arterial responses both inside
nd outside the stent as long as 28 months after implanta-
ion of the AMS by using serial quantitative angiographic
nd IVUS analysis in event-free patients.
ethods
he PROGRESS-AMS clinical trial was designed as a
onrandomized, prospective, multicenter trial to evaluate
he efficacy and safety of an absorbable magnesium alloy
tent (BIOTRONIK AG, Zurich, Switzerland) (20). The oagnesium AMS geometrical design and mechanical prop-
rties have been described previously (14–17).
The methodology of the PROGRESS study was pub-
ished previously (20). In brief, 63 patients in 8 centers with
nginal symptoms and single de novo lesions with reference
essel diameters of 3.0 to 3.5 mm and lesion lengths 15
m in native coronaries were enrolled. Seventy-one stents,
0 to 15 mm in length and 3.0 to 3.5 mm in diameter, were
uccessfully implanted after pre-dilation in 63 patients.
VUS analysis. Intravascular ultrasound was performed in 52
atients with a mechanical rotating element 40-MHz trans-
ucer (Atlantis IVUS catheter and Galaxy II console,
oston Scientific, Natick, Massachusetts) and in 13 patients
rom 2 centers with a synthetic aperture electronic system 20
Hz (Eagle Eye, Volcano, Rancho Cordova, California)
ith acquisition started after activation of a motorized
ullback at 0.5 mm/s. All patients underwent angiographic
nd IVUS follow-up at 4 months. Nine patients underwent
ate IVUS follow-up (study
anges from 12 to 28 months).
omputerized planimetry mea-
ured the reference segment ex-
ernal elastic membrane (EEM),
tent, and lumen every millime-
er within the stent. Neointima
as calculated as stent minus lu-
en measures, whereas volumes
ere calculated by the summation
f areas. Qualitative and quantita-
ive IVUS assessment was per-
ormed by an independent core
aboratory (Washington Hospital
enter, Washington, DC). The
VUS characteristics were identi-
ed according to the criteria of the
merican College of Cardiology
linical Expert Consensus document on the IVUS exami-
ations performed before and after stenting and at
ollow-up (21). Quantitative measurements included EEM
rea, luminal area, and plaque and media area, which at
ollow-up could be further divided into neointimal area
nside the stent struts and original plaque outside. The
roximal and distal reference segments selected for analysis
ad the most normal-looking cross-section within 10 mm
roximal and distal to the lesion. The average of the
roximal and distal reference EEM and lumen cross sec-
ional area (CSA) were used to assess stent expansion,
efined as: minimal stent CSA/reference lumen CSA 100
21). Stent malapposition was defined as a lack of contact
etween any stent strut and the underlying vessel wall (22).
ong-term angiographic and IVUS analysis. The study pro-
ocol was amended to include late angiographic and IVUS
ong-term follow-up, to further evaluate the natural history
Abbreviations
and Acronyms
AMS  absorbable metal
stent(s)
BMS  bare-metal stent(s)
CSA  cross sectional area
DES  drug-eluting stent(s)
DS  diameter stenosis
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
LLL  late lumen loss
MLD  minimum lumen
diameterf vascular responses to the AMS. Of the initial 63 patients,
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314patients without any clinical events, including revascular-
zation, through the 28-month follow-up with serial (after
rocedure, 4-month, and late follow-up [12 to 28 months])
nd analyzable IVUS data were selected for this substudy.
uantitative IVUS and angiographic analysis. The quantita-
ive coronary angiography (QCA) analyses were performed
y an independent core laboratory (Cardialysis, Rotterdam,
he Netherlands). The serial IVUS (after procedure,
-month, and late follow-up) procedures were performed
fter administration of 200 g intracoronary nitroglycerin
ith an automated pullback at 0.5 mm/s. All IVUS proce-
ures were recorded on VHS videotape, and the images
ere digitized for analysis. Two coronary segments were
ubjected to coronary angiography: in-stent and -lesion.
he in-stent analysis encompassed only the 10- to 15-mm-
ong segment covered by the stent. The in-lesion segment
as defined as the stent plus 5 mm proximal and 5 mm
istal to the edge or the nearest side branch. In-stent and
n-lesion restenosis were defined as 50% DS at follow-up
ithin the stent and target lesion, respectively. Minimum
umen diameter (MLD) and percent DS were measured for
ach segment. In-stent late lumen loss (LLL) was calculated
s post-procedural MLD minus follow-up MLD. Intimal
yperplasia volume was calculated as stent volume minus
uminal volume. Percent intimal hyperplasia was defined as
ntimal hyperplasia volume/stent volume.
tatistics. Descriptive statistics reported mean values, SD or
edian, and range for continuous data sets and absolute and
elative frequencies for categorical data. Comparisons be-
ween the same measurements at different time points were
erformed with a 2-tailed paired t test or the Wilcoxon
igned-rank test. A probability value 0.05 was considered
tatistically significant. The SAS 9.1 software (SAS, Cary,
orth Carolina) was used.
esults
atients and procedural characteristics. The patient and
rocedural characteristics for the group that had serial (after
he procedure, at 4 months, and at late follow-up) IVUS
xaminations compared with the entire PROGRESS study
ohort are displayed in Table 1. Comparable baseline
emographic and angiographic data indicate that the data in
he serial IVUS cohorts are representative of the overall
andomized study population (Tables 1 and 2).
uantitative angiographic results. The baseline angiographic
ndexes and the post-implantation angiographic results of the
roup with serial long-term follow-up were similar to the
ntire cohort (Table 2). The follow-up angiographic analysis of
he group with serial angiographic studies is displayed in Table
. Overall 8 subjects underwent repeat angiography between 12
nd 28 months after implantation, with available QCA ana-
yzable films. The median difference between in-stent late loss
t 4 months and the late follow-up was 0.23 mm (range w0.93 to 0.05), with a median reduction of 8% in DS. A
imilar observation was made for in-segment difference in late
oss with a median of 0.32 mm (range 0.92 to 1.29) and
eduction median in-segment DS from 21.5% to 12% at 4
onths and the late follow-up, respectively. Furthermore, the
n-stent MLD was stable or increased from that at 4 months to
he long-term follow-up with the median long-term follow-up
LD of 2.17 mm and a difference between follow-ups of 0.22
m. All but 1 patient increased a minimum of 0.1 mm
etween follow ups; this patient had a stagnant MLD of 2.3 at
oth 4-month and long-term follow-ups.
VUS results. The overall analysis included 32 subjects who
ad IVUS images acquired before the AMS implantation,
7 studies immediately after implantation, and 48 studies at
months, and overall 35 pair analysis after AMS implan-
ation IVUS examination detected thick stent struts, which
ere well apposed to the vessel wall (Fig. 1). The overall
nal minimum stent CSA was 6.2  1.5 mm2.
hanges up to 4 months. At 4 months’ follow-up, the
trut echoreflectivity was drastically diminished, yet it
Table 1. Baseline Clinical Characteristics of the Study Population and of
IVUS Subset Population
Overall Study
Population
(n  63)
Long-Term Follow-Up
Subset
(n  8)*
Age (yrs), mean  SD 61.3  9.5 62.8  7.1
Male 44 (70) 7 (78)
Stable angina 52 (83) 8 (89)
Unstable angina 6 (10) 1 (11)
Prior CABG 3 (5) 0 (0)
Prior myocardial infarction 26 (41) 6 (67)
Prior PCI 15 (24) 2 (22)
Prior PCI of the target vessel 14 (22) 2 (22)
History of CVA or TIA 1 (2) 0 (0)
History of PVD 4 (6) 1 (11)
History of diabetes 11 (18) 0 (0)
Insulin dependent diabetes 3 (5) 0 (0)
Any smoking history 30 (48) 6 (67)
Hypertension 41 (65) 8 (89)
Hyperlipidemia 39 (62) 5 (56)
Lesions treated
RCA 23 (37) 3 (33)
LAD 22 (35) 2 (22)
LCX 18 (29) 4 (44)
ACC/AHA lesion type A 31 (49) 4 (44)
ACC/AHA lesion type B1/B2 32 (51) 5 (56)
ACC/AHA lesion type C 0 (0) 0 (0)
Values are n(%), unless otherwise indicated. *There are no statistical differences between the
patients who underwent serial follow-up and those who did not (Fisher exact test).
ACC/AHA  American College of Cardiology/American Heart Association; CABG  coronary
artery bypass graft surgery; CVA  cerebrovascular accident; LAD  left anterior descending
artery; LCX  left circumflex artery; RCA  right coronary artery; PCI  percutaneous coronary
intervention; PVD peripheral vascular disease; TIA transient ischemic attack.as still possible to identify their original position as
s
s
t
t
t
a
t
d
o
e
1
o
s
C
f
b
s
a
a
t
t
f
4
o
p
D
T
s
a
A
erial fol
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 4 , 2 0 0 9
A P R I L 2 0 0 9 : 3 1 2 – 2 0
Waksman et al.
The PROGRESS-AMS Trial
315mall circular areas with higher echo reflection than the
urrounding tissue but without shadowing (Fig. 1). With
hese areas as markers indicating the border zone between
he original plaque and the neointima, the mechanism of
he structural changes leading to lumen loss at follow-up
fter implantation of an AMS stent could be quantita-
ively analyzed. The overall IVUS indexes analysis is
isplayed in Table 4. The LLL was the combined effect
f a decrease in EEM area and of the area originally
ncircled by the stent (42%, 18.9  45.4 mm3, and
8%, 23.9  32.9 mm3) and neointima formation (40%
f the entire LLL, 20.1  14.7 mm3), with no
ignificant changes in the original plaque (Fig. 2).
hanges from 4 months to 12 to 28 months. At later
ollow-up, the location of the stents was assisted by side
ranches, because there was no evidence of the presence of
Table 2. Baseline Angiographic Characteristics of the Study Population a
Angiographic characteristic before stenting
Reference diameter (mm)
Minimal luminal diameter (mm)
Diameter stenosis (%)
Lesion length (mm)
Angiographic characteristic after stenting
Reference diameter (mm)
Stented length (mm)
In-segment minimal luminal diameter (mm)
In-segment diameter stenosis (%)
In-segment acute gain (mm)
Proximal margin minimal luminal diameter (mm)
In-stent minimal luminal diameter (mm)
Distal margin minimal luminal diameter (mm)
Proximal margin diameter stenosis (%)
In-stent diameter stenosis (%)
Distal margin diameter stenosis (%)
In-stent acute gain (mm)
Values are mean (SD), n. There are no statistical differences between the patients who underwent s
Table 3. Angiographic Characteristics for the 8 Patients Undergoing Serial
Baseline, After Sten
Reference vessel diameter, mm 2.8 (1.9 to 3.5)
In-stent diameter stenosis, % 12 (4 to 27)
In-stent minimal luminal diameter, mm 2.6 (2.0 to 3.1)
In-stent late loss, mm —
In-segment diameter stenosis, % 25.5 (16 to 34)
In-segment minimal luminal diameter, mm 2.0 (1.3 to 3.0)
In-segment late loss, mm —
Change between follow-up, mm
Delta in-stent late loss —
Delta in-segment late loss —Values are median (range).truts (Fig. 3). Furthermore, there was neither calcification nor
ny adverse vascular changes seen by IVUS. The IVUS indexes
t follow-up after 4 months remained stable over the course of
he long-term follow-up and are displayed in Table 5. Overall
here was not a significant change from 4 months to the later
ollow-up time points for all IVUS indexes as shown in Figure
. Furthermore, at long-term follow-up there was no evidence
f aneurysm formation or calcifications at the site of the
reviously stented segment and at the edges.
iscussion
his paper presents the first long-term (up to 28 months)
erial angiographic and IVUS analyses after deployment of
n AMS. The analysis detected the main features of the
MS in patients who underwent coronary implantation: 1)
the Long-Term Follow-Up Subset Population
ll Study Population Long-Term Follow-Up Subset
2.75 (0.47), 63 2.97 (0.43), 7
1.05 (0.38), 62 0.95 (0.44), 7
1.48 (13.10), 62 68.07 (15.42), 7
9.84 (3.97), 59 9.90 (6.30), 6
2.68 (0.46), 60 2.78 (0.56), 8
2.79 (3.73), 60 12.42 (3.25), 8
2.17 (0.38), 60 2.09 (0.52), 8
0.50 (7.50), 60 24.88 (7.38), 8
1.11 (0.42), 59 1.14 (0.56), 8
2.60 (0.47), 60 2.57 (0.45), 7
2.46 (0.37), 60 2.56 (0.41), 8
2.28 (0.44), 60 2.16 (0.54), 7
1.87 (8.47), 60 13.29 (12.89), 7
2.43 (5.64), 60 13.29 (9.46), 7
6.66 (9.11), 60 21.93 (9.16), 7
1.41 (0.45), 59 1.60 (0.45), 8
low-up and those who did not.
w-Up
4 Months Follow-Up >12 Months Follow-Up
2.9 (2.3 to 3.3) 3.3 (2.3 to 3.6)
35.5 (14 to 57) 24.5 (11 to 44)
1.8 (1.1 to 2.6) 2.2 (1.6 to 2.9)
0.66 (0.1 to 1.66) 0.44 (0.09 to 0.73)
37 (14 to 57) 30.5 (11 to 61)
1.7 (1.1 to 2.6) 2.0 (1.4 to 2.4)
0.2 (0.4 to 1.5) 0.1 (0.4 to 0.9)
— 0.2 (0.9 to 0.1)
— 0.3 (0.9 to 1.3)nd of
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316mmediate after deployment of the AMS with some addi-
ional use of post-balloon dilation, the stent is well-
xpanded with adequate apposition to the vessel wall;
owever, the final CSA of the AMS seems to be smaller
hen compared with the 1 obtained with nonabsorbable
etallic stents; 2) the main mechanisms for restenosis with
he AMS are early recoil (negative remodeling of the vessel
rea) and modest neointima formation; 3) as seen in the
urrent study the stents are degraded fast and undergo
early complete degradation at 4 months; 4) after complete
egradation there is stability and durability of the vessel
ndexes (up to 28 months); and 5) there are no adverse
ffects to the vessel wall at the site and the edges of where
he AMS was implanted.
arly IVUS ﬁndings after AMS implantation. The IVUS
maging immediately after AMS implantation detected
hick struts with adequate expansion and apposition of the
tent to the vessel wall. Post-balloon dilation to optimize
he deployment results was required in 42 patients (66.7%),
hich is an acceptable rate for stent technology. Despite this
act, the mean stent CSA of the AMS after implantation
as 6.2 1.5 mm2, which is lower than the minimum CSA
f nondegradable metallic stents reported previously with
are metal stents (BMS) for similar vessel sizes (3.0 to 3.5
m). In the Taxus II (Boston Scientific, Natick, Massa-
husetts) study, the BMS minimum CSA was 8.1  2.5
m2 (23). The AMS stent volume after implantation was
16.5 40.2 mm3, which is lower when compared with the
tent volume of the BMS in the Taxus IV study (151  56
m3). Thus, the initial implantation of the AMS has less
xpansion and less stent volume when compared with
tainless steel metallic stents (24). These differences might
esult from differences in the radial force, which is lower in
onstrating adequate expansion and apposition of the stents to the vessel
e 4 months of the follow-up.Figure 1. Absorbable Metal Stent After Implantation and at 4 Months’ Follow-Up
Intravascular ultrasound imaging after implantation and at 4 months’ follow-up, demTable 4. IVUS Characteristics for all Patients at 4 Months Follow-Up
Overall n
Before
Minimum stent CSA (mm2) 5.4 1.5 32
Minimum vessel CSA (mm2) 15.4 4.8 30
After
Stent length index (mm) 15.9 4.1 50
Minimum stent CSA (mm2) 6.2 1.5 57
Minimum vessel CSA (mm2) 14.6 4.2 56
Stent volume index (mm3) 116.5 40.2 50
Lumen volume index (mm3) 116.9 40.0 50
EEM volume index (mm3) 254.4 84.4 45
4 months follow-up
Stent length follow-up (mm) 16.2 4.1 42
Minimum stent CSA, follow-up (mm2) 4.2 1.6 48
Minimum vessel CSA, follow-up (mm2) 12.6 4.4 48
Stent volume follow-up (mm3) 95.0 38.9 42
Lumen volume follow-up (mm3) 74.9 32.8 42
EEM volume follow-up (mm3) 242.8 87.4 40
Intimal hyperplasia follow-up (mm3) 20.4 14.4 42
Extra-stent neointima follow-up (mm3)
(deﬁned as EEM volume  stent volume)
148.4 53.9 42
Net volume obstruction (%) 21.8 11.0 42
Change from baseline to 4 months follow-up
Minimum stent CSA change (mm2) 2.0 1.3 43
Minimum vessel CSA change (mm2) 1.8 1.9 42
Stent volume change (mm3) 23.9 32.9 35
Lumen volume change (mm3) 45.2 40.5 35
EEM volume change (mm3) 18.9 45.4 29he magnesium when compared with the stainless steel
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317lloy, by immediate recoil after implantation as seen at
ost-balloon angioplasty or by a combination of the two.
hese IVUS results are concordant with the angiographic
CA results, which measured in-stent MLD immediately
fter stenting as 2.47  0.37 mm, whereas the reference
essel was measured at 2.74  0.42 mm. Because the
Figure 2. Mechanism of Absorbable Metal Stent Restenosis
Mechanism of absorbable metal stent restenosis, demonstrating the relative co
stent (intra-stent) and outside of the stent (extra-stent).
Figure 3. Complete Degradation of Absorbable Metal Stent at 4 and 16 MoSerial intravascular ultrasound imaging after implantation, at 4 and 16 months, demngiographic elastic recoil after implantation was calculated
nly as 7  15%, it is probable that differences between the
istorical reported lumen volume and the AMS lumen
olume are mainly due to differences in stent expansion due
o the weakness of the magnesium alloy when compared
ith stainless steel or cobalt chromium. This suggests that,
tion of the components of restenosis: stent recoil and neointima within thentribunthsonstrating degradation of the struts with preservation of the lumen.
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318hen implanting AMS, the “bigger the better” lumen
heory on implantation is applicable and the focus should be
n obtaining larger lumen perhaps by post-dilation with
emi-compliant balloons.
VUS ﬁndings of the AMS from implantation up to 4 months.
he main findings at this time frame suggest that early
ecoil with 42% reduction in EEM is a major contributor for
he LLL and restenosis. This reduction in EEM, which is
ot seen in nondegradable metallic stents, can be attributed
o early and fast degradation and loss of the radial force,
erhaps even few weeks after AMS implantation. An IVUS
tudy in 1 patient who was brought to an earlier study at 3
Table 5. IVUS Data >12 Months (Average Time to IVUS 20.3  6.4 Month
Baseline, After St
Minimum stent CSA (mm2) 5.7 (4.2 to 7.8), 7
Minimum vessel CSA (mm2) 13.9 (8.1 to 19.9),
Stent volume (mm3) 124.5 (82.9 to 136
Lumen volume (mm3) 124.5 (82.9 to 136
EEM volume (mm3) 234.5 (156.7 to 30
Intimal hyperplasia (mm3) —
Extra-stent neointima (mm3)
(deﬁned as EEM volume  stent volume)
—
Net volume obstruction (%) —
Change between follow-up
Minimum stent CSA change (mm2) —
Minimum vessel CSA change (mm2) —
Stent volume change (mm3) —
Lumen volume change (mm3) —
EEM volume change (mm3) —
Values are median (range), n. No statistical significance at the 0.05 level (signed rank test).
Abbreviations as in Table 4.
Figure 4. Intravascular Ultrasound Indexes of Absorbable Metal Stent
From Index Through Long-Term Follow-Up
Intravascular ultrasound indexes at 4 months through long-term follow-up
(FU) demonstrating durability of the results from 4 months to late follow-d
up. CSA  cross sectional area; IH  intimal hyperplasia.eeks after implantation due to atypical chest pain indicated
hat the nearly 50% of the stent struts were degraded, thus
uggesting a degradation rate immediately after AMS im-
lantation faster than initially expected. Although the pa-
ient did not experience compromised lumen or stent
alapposition at that early time point, restenosis was
etected at 4 months—mainly due to recoil. Thus, it is
onceivable that the early and fast degradation of the stent
ass significantly weakened the radial force of the stent and
ould be the main cause for the early vessel recoil that does
ot have enough stent support to prevent early and late
essel contraction as part of the vessel’s healing process.
The question of how long we need the stent to support
he vessel wall after deployment has never been convincingly
nswered. With BMS, endothelialization is nearly complete
t 1 month, but does that mean that stent scaffolding is not
eeded beyond this time point? In the present study the
tent was nearly completely degraded at 4 months, but the
uestion is how much of the stent was degraded at 1 month
nd whether there was enough radial support at 1 month to
revent recoil. Thus the question with bioabsorbable stents
hould not focus only on the overall degradation time but on
he rate of degradation or the degradation kinetics. Very
arly and fast degradation will result in loss of radial force
ithin weeks or days and could lead to early recoil. Because
e did not observe further recoil from 4 months up to 28
onths we can assume that there is no need for further
caffolding beyond 4 months and, hence, degradation times
eyond this point. To address the recoil phenomenon seen
ith the AMS, several approaches can be taken to modify
he overall degradation and the degradation rate; among
hem are change in the alloy composition, change in stent
4 Months Follow-Up >12 Months Follow-Up
3.6 (2.5 to 7.2), 7 4.0 (1.9 to 8.3), 8
14.0 (7.3 to 19.8), 7 9.9 (5.8 to 20.8), 8
106.0 (69.3 to 158.8), 7 94.2 (46.7 to 171.2), 7
100.9 (50.7 to 129.1), 7 93.0 (40.6 to 140.0), 7
259.9 (142.7 to 345.5), 6 203.8 (122.1 to 324.7), 6
14.6 (2.9 to 29.7), 7 6.3 (1.2 to 31.1), 7
137.3 (73.4 to 186.8), 6 106.2 (68.0 to 153.5), 6
10.2 (4.2 to 27.5), 7 11.0 (1.3 to 18.2), 7
— 0.6 (1.4 to 1.6), 7
— 0 (2.5 to 2.2), 7
— 4.5 (4.4 to 16.1), 6
— 7.6 (8.0 to 22.4), 6
— 1.2 (38.4 to 6.7), 5s)
enting
7
.8), 5
.8), 5
3.9), 3esign and strut thickness, and passivation technology, and
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319he like. The neointima formation component of the reste-
osis seen with AMS was modest when compared with
revious studies with BMS. The intimal volume of the
MS at 4 months (20.4  14.4 mm3) was less than that
eported for the Express stent at 9 months (41  23 mm3)
ut still higher when compared with the Taxus stent at 9
onths (18 18 mm3) (24). The relatively lower neointima
n the AMS compared with BMS technology could be
xplained by the fact that the stent is degraded with a
ecrease in strut thickness and elimination of the stent,
herefore, the trigger for neointima formation is gone.
hese lower indexes on neointima rule out a massive
nflammatory process during the degradation process. Al-
hough the time frame is different, given the fact that there
as no more neointima formation reported in the AMS
roup after 4 months, it is possible that if the recoil
henomenon was eliminated from the equation, the AMS
ould compete with the Taxus stent in terms of restenosis.
he question remains as to whether the recoil can be
liminated and, if so, at what price.
One of the questions with bioabsorbable stents is
elated to their degradation products and what is left on
he arterial wall. Prior animal studies with the AMS
emonstrated a compound including phosphate and cal-
ium in the vessel wall (15), leading to reflections seen by
VUS, but unlike the metallic struts, they are seen
ithout shadows, which help to differentiate this material
rom metal. Overall, there was some variability in degra-
ation, because it was completed 4 times in all patients,
ut no documented distal embolization was seen in any of
he patients. Furthermore, at longer follow-up, the re-
ections were not detected, which ruled out late calcifi-
ations after degradation of the AMS.
VUS ﬁndings of the AMS after 4 months. The long-term
ngiogram and IVUS observations up to 28 months in 8
atients who did not experience an event at 4 months
eassured us that there is no late development of neointima
ormation or late recoil beyond the 4 months’ time point.
n the contrary, in some patients there was evidence of
egression in the neointima, and in some patients we
bserved an increase in vessel and lumen volume by IVUS.
his was supported by the QCA analysis that demonstrated
verall negative late loss at the previously stented segment.
inally there was no other IVUS or angiographic adverse
ndings, including evidence of calcifications or aneurysms,
t the previously stented segments, including the edges.
The stability and durability of the results after 4 months
hen the AMS reached complete degradation suggests that
ith AMS perhaps 4-month results can predict the long-
erm outcome of the vessel and its edges. If this is true, it is
ifferent from the BMS or DES that require much longer
ime for follow-up until stability is obtained. This difference
an be explained by the nearly complete degradation of the
MS at 4 months. pThe present study used the AMS without drug elution
rom the stent and resulted in higher restenosis, which was
nticipated due to unexpected recoil phenomenon, most
ikely resulting from an early loss of radial support. An
nimal study using vascular brachytherapy with beta radia-
ion as adjunct therapy to AMS implantation in porcine
oronary arteries demonstrated a reduction in the neointima
ormation but did not have an impact on the recoil after 30
ays of stent implantation (25). Therefore, it is likely that a
rug-eluting AMS with the current alloy and stent design
ould probably not have impacted the recoil phenomenon
ut would have reduced the neointima formation as re-
orted in the bioabsorbable everolimus-eluting stent, which
emonstrated LLL (0.44 mm) (26) compared with the
MS (0.87 mm) but higher late loss when compared with
he Xience (Abbott Laboratories, Abbott Park, Illinois)
tent (0.10 mm) with the same drug (27). Therefore, to
educe the recurrence rate with the AMS, efforts should be
irected first to improve its mechanical integrity. This can
e done by changing the alloy composition and the stent
esign and perhaps by means of passivation that will slow
he initial degradation kinetics. Drug elution might further
ontribute to a reduction of the neointima and to acceptable
ate loss and restenosis rates. The comforting results of the
resent study are that once this goal is obtained there will be
urability and stability of the results over the first months
fter implantation.
tudy limitations. The current observation is limited to a
mall cohort of patients who were enrolled in the first
easibility study with AMS. An even smaller number of
atients were available for the later angiographic and IVUS
ollow-up time points. In addition, the late follow-up was
ot consistent and ranged from 12 to 28 months. Never-
heless, the IVUS findings available after implantation and
t follow-up and the late angiographic and IVUS availability
t later time points enabled us to understand the current
ehavior, benefits, and limitations of this technology and
ssist in the planning of an improved version of the AMS to
e tested in the future.
onclusions
VUS imaging of the AMS in human coronaries identified
arly recoil as a main contributor for restenosis at 4 months.
ate IVUS imaging supports the safety profile of AMS—
ith nearly complete degradation at 4 months and durabil-
ty of the results without any early or late adverse findings.
fforts to improve the radial force of the stent and the
egradation kinetics are warranted to eliminate early recoil
nd improved patency rates of the AMS when absorption is
omplete. Drug elution of the AMS might be mandatory to
inimize the neointima formation and to maintain suffi-
ient lumen, if the recoil component remains despite the
lanned iterations in the AMS technology.
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